Evidence map›Paper›PMID 33427938›Full record

ArticleActa neuropathologica2021

Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation.

Luis Aragão Gomes, Valerie Uytterhoeven, Diego Lopez-Sanmartin, Sandra O Tomé, Thomas Tousseyn, Rik Vandenberghe, Mathieu Vandenbulcke, Christine A F von Arnim, Patrik Verstreken, Dietmar Rudolf Thal

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neuropathologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Luis Aragão GomesLaboratory for Neuropathology, Department of Imaging and Pathology, KU-Leuven, Herestraat 49, 3000, Leuven, Belgium. luis_gomes19@hotmail.com.
Valerie UytterhoevenLeuven Brain Institute, KU-Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0003-3100-2079
Diego Lopez-SanmartinLaboratory for Neuropathology, Department of Imaging and Pathology, KU-Leuven, Herestraat 49, 3000, Leuven, Belgium.
Sandra O ToméLaboratory for Neuropathology, Department of Imaging and Pathology, KU-Leuven, Herestraat 49, 3000, Leuven, Belgium.
Thomas TousseynDepartment of Pathology, UZ-Leuven, Leuven, Belgium.
Rik VandenbergheLeuven Brain Institute, KU-Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0001-6237-2502
Mathieu VandenbulckeLeuven Brain Institute, KU-Leuven, Leuven, Belgium.
Christine A F von ArnimDepartment of Neurology, University of Ulm, Ulm, Germany.ORCID http://orcid.org/0000-0002-8614-2223
Patrik VerstrekenLeuven Brain Institute, KU-Leuven, Leuven, Belgium.
Dietmar Rudolf ThalLaboratory for Neuropathology, Department of Imaging and Pathology, KU-Leuven, Herestraat 49, 3000, Leuven, Belgium. Dietmar.Thal@kuleuven.be.ORCID http://orcid.org/0000-0002-1036-1075

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Alzheimer's disease (AD), tau-protein undergoes a multi-step process involving the transition from a natively unfolded monomer to large, aggregated structures such as neurofibrillary tangles (NFTs). However, it is not yet clear which events initiate the early preclinical phase of AD tauopathy and whether they have impact on the propagation of tau pathology in later disease stages. To address this question, we analyzed the distribution of tau species phosphorylated at T231, S396/S404 and S202/T205, conformationally modified at the MC1 epitope and fibrillary tau detected by the Gallyas method (Gallyas-tau), in the brains of 15 symptomatic and 20 asymptomatic cases with AD pathology as well as of 19 nonAD cases. As initial tau lesions, we identified phosphorylated-T231-tau diffusely distributed within the somatodendritic compartment (IC-tau) and phosphorylated-S396/pS404-tau in axonal lesions of the white matter and in the neuropil (IN-tau). The subcellular localization of pT231-tau in the cell body and pS396/pS404-tau in the presynapse was confirmed in hP301L mutant Drosophila larvae. Phosphorylated-S202/T205-tau, MC1-tau and Gallyas-tau were negative for these lesions. IC- and IN-tau were observed in all analyzed regions of the human brain, including early affected regions in nonAD cases (entorhinal cortex) and late affected regions in symptomatic AD cases (cerebellum), indicating that tau pathology initiation follows similar processes when propagating into previously unaffected regions. Furthermore, a sequence of AD-related maturation of tau-aggregates was observed, initiated by the appearance of IC- and IN-tau, followed by the formation of pretangles exhibiting pT231-tau, pS396/pS404-tau and pS202/pT205-tau, then by MC1-conformational tau, and, finally, by the formation of Gallyas-positive NFTs. Since cases classified as nonAD [Braak NFT stages < I (including a-1b)] already showed IC- and IN-tau, our findings suggest that these lesions are a prerequisite for the development of AD.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAnimalsAutopsyCerebellumCytoplasmDrosophilaEntorhinal CortexFemaleHumansImmunohistochemistryLarvaMaleMiddle AgedNeurofibrillary TanglesMAPT protein, humantau ProteinsNeuropathologyPreclinical Alzheimer’s diseaseSite-specific phosphorylationTau modificationTau-protein

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.